Open-label, single-arm phase Ib/II study of immune combination therapy with elotuzumab and belantamab mafodotin in patients with relapsed refractory multiple myeloma

被引：0
|
作者：
Browning, Sabrina
Li, Fangyong
Parker, Terri L.
Bar, Noffar
Anderson, Tara
Stevens, Erica
VanOudenhove, Jennifer
Matthews, Martin
Gorshein, Elan
Talsania, Ashita D.
Sabbath, Kert D.
Seropian, Stuart
Halene, Stephanie
Neparidze, Natalia
机构：
[1] Yale Sch Med, Div Hematol, Dept Internal Med, New Haven, CT USA
[2] Yale Sch Publ Hlth, New Haven, CT USA
[3] Yale New Haven Hosp, New Haven, CT USA
[4] Yale Univ, Div Hematol, New Haven, CT USA
[5] Yale Canc Ctr, Div Hematol, New Haven, CT USA
[6] Yale Univ, Div Hematol, Shool Med, New Haven, CT USA
[7] Yale Univ, New Haven, CT USA
[8] Yale Univ, Yale Canc Ctr, New Haven, CT USA
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2024年 / 42卷 / 16期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
7559
引用
收藏
页数：1
相关论文
共 50 条
  • [41] Efficacy and safety of venetoclax in combination with cytarabine and azacitidine (VAA) in relapsed/refractory acute myeloid leukemia: An open-label, single-arm, phase II study.
    You, Liangshun
    Liu, Yi
    Mai, Wenyuan
    Zhou, De
    Xie, Wanzhuo
    Mao, Liping
    Zhou, Xinping
    Tong, Hongyan
    Jin, Jie
    Meng, Haitao
    JOURNAL OF CLINICAL ONCOLOGY, 2023, 41 (16)
  • [42] Initial Results of PX-171-004, An Open-Label, Single-Arm, Phase II Study of Carfilzomib (CFZ) in Patients with Relapsed Myeloma (MM)
    Vu, Ravi
    Wang, Michael
    Orlowski, Robert
    Stewart, A. Keith
    Jagannath, Sundar
    Kukreti, Vishal
    Taylor, Jessica
    Fuhrman, Diana
    Cruickshank, Scott
    Schwartz, Richard
    Kunkel, Lori
    Siegel, David
    BLOOD, 2008, 112 (11) : 320 - 320
  • [43] A phase II study of elotuzumab in combination with pomalidomide, bortezomib, and dexamethasone in relapsed and refractory multiple myeloma.
    Yee, Andrew Jenho
    Laubach, Jacob
    Campagnaro, Erica Leigh
    Lipe, Brea
    Nadeem, Omar
    Cole, Craig
    O'Donnell, Elizabeth
    Schlossman, Robert L.
    Bianchi, Giada
    Branagan, Andrew Robert
    Shapiro, Samantha J.
    Harrington, Cynthia C.
    Burke, Jill N.
    Gammon, Marilyn T.
    Lively, Kathleen J.
    Thorburn, Cassandra Ann
    Mann, Mason L.
    Lohr, Jens Guenter
    Richardson, Paul G.
    Raje, Noopur S.
    JOURNAL OF CLINICAL ONCOLOGY, 2018, 36 (15)
  • [44] Final results of PX-171-003-A0, part 1 of an open-label, single-arm, phase II study of carfilzomib (CFZ) in patients (pts) with relapsed and refractory multiple myeloma (MM)
    Jagannath, S.
    Vij, R.
    Stewart, K.
    Somlo, G.
    Jakubowiak, A.
    Trudel, S.
    Schwartz, R.
    Siegel, D.
    Kunkel, L.
    JOURNAL OF CLINICAL ONCOLOGY, 2009, 27 (15)
  • [45] Efficacy and safety of melphalan, arsenic trioxide and ascorbic acid combination therapy in patients with relapsed or refractory multiple myeloma: a prospective, multicentre, phase II, single-arm study
    Berenson, James R.
    Boccia, Ralph
    Siegel, David
    Bozdech, Marek
    Bessudo, Alberto
    Stadtmauer, Edward
    Pomeroy, J. Talisman
    Steis, Ronald
    Flam, Marshall
    Lutzky, Jose
    Jilani, Syed
    Volk, Joseph
    Wong, Siu-Fun
    Moss, Robert
    Patel, Ravi
    Ferretti, Delina
    Russell, Kit
    Louie, Robert
    Yeh, Howard S.
    Swift, Regina A.
    BRITISH JOURNAL OF HAEMATOLOGY, 2006, 135 (02) : 174 - 183
  • [46] Trial in Progress: Phase I Open-Label Study of Metformin and Nelfinavir in Combination with Bortezomib in Patients with Relapsed and/or Refractory Multiple Myeloma
    Gonsalves, Wilson I.
    Kumar, Shaji
    Perez, Gabriela
    Saathoff, Stephanie
    Wilson, Diana M.
    Young, Anna
    Ailawadhi, Sikander
    BLOOD, 2021, 138
  • [47] An open-label, multicenter, phase Ib study of daratumumab in combination with backbone regimens in patients with multiple myeloma
    Comenzo, Raymond
    Moreau, Philippe
    Mateos, Maria-Victoria
    Blade, Joan
    Benboubker, Lotfi
    de la Rubia, Javier
    Facon, Thierry
    Fay, Joseph
    Qin, Xiang
    Masterson, Tara
    Schecter, Jordan
    Ahmadi, Tahamtan
    San-Miguel, Jesus
    CANCER RESEARCH, 2015, 75
  • [48] An open-label single-arm phase II study of regorafenib for the treatment of angiosarcoma
    Agulnik, Mark
    Schulte, Brian
    Robinson, Steven
    Hirbe, Angela C.
    Kozak, Kevin
    Chawla, Sant P.
    Attia, Steven
    Rademaker, Alfred
    Zhang, Hui
    Abbinanti, Susan
    Cehic, Rasima
    Monga, Varun
    Milhem, Mohammed
    Okuno, Scott
    Van Tine, Brian A.
    EUROPEAN JOURNAL OF CANCER, 2021, 154 : 201 - 208
  • [49] Efficacy and safety of single-agent belantamab mafodotin versus pomalidomide plus low-dose dexamethasone in patients with relapsed or refractory multiple myeloma (DREAMM-3): a phase 3, open-label, randomised study
    Dimopoulos, Meletios Athanasios
    Hungria, Vania T. M.
    Radinoff, Atanas
    Delimpasi, Sosana
    Mikala, Gabor
    Masszi, Tamas
    Li, Jian
    Capra, Marcelo
    Maiolino, Angelo
    Pappa, Vasiliki
    Chraniuk, Dominik
    Osipov, Iurii
    Leleu, Xavier
    Low, Michael
    Matsumoto, Morio
    Sule, Neal
    Li, Mary
    McKeown, Astrid
    He, Wei
    Bright, Shelley
    Currie, Brooke
    Perera, Sue
    Boyle, Julia
    Roy-Ghanta, Sumita
    Opalinska, Joanna
    Weisel, Katja
    LANCET HAEMATOLOGY, 2023, 10 (10): : E801 - E812
  • [50] Real-world experience with belantamab mafodotin therapy for relapsed/refractory multiple myeloma: A multicentre retrospective study
    Shragai, Tamir
    Magen, Hila
    Lavi, Noa
    Gatt, Moshe
    Trestman, Svetlana
    Zektser, Miri
    Ganzel, Chezi
    Jarchowsky, Osnat
    Berger, Tamar
    Tadmor, Tamar
    Leiba, Merav
    Hertzog-Tzarfaty, Katrin
    Horowitz, Netanel
    Shapira, Michael
    Varssano, David
    Berger, Yoav
    Frenkel, Shahar
    Krauthammer, Mark
    Avivi, Irit
    Luttwak, Efrat
    Cohen, Yael C.
    BRITISH JOURNAL OF HAEMATOLOGY, 2023, 200 (01) : 45 - 53
12345